Abstract

  In December 31, 2019, hospitals pronounced a cluster of instances with pneumonia of unknown motive in Wuhan, Hubei, China, attracting brilliant interest nationally and worldwide. The pandemic of coronavirus disease 2019 precipitated by means of the SARS-CoV-2 offers an unheard of venture to discover superb capsules for treatment. Given the speedy tempo of scientific discovery and medical statistics generated by means of the massive quantity of human beings unexpectedly contaminated by using SARS-CoV-2, clinicians want correct proof involving nice clinical remedies for this infection. This paper analysis the literature on all on hand records about the Treatments of COVID-19. Treatments, together with Antibodies, Vaccines, antiviral agents, convalescent plasma transfusion, corticosteroids, chloroquine and hydroxychloroquine, are mentioned in this article.

Keywords: Coronavirus Disease 2019; SARS-CoV-2; Vaccines; Treatment; Antibodies; Antiviral Agents; Crticosteroids; Chloroquine and Hydroxychloroquine

References

1. Liu Y., et al. “The reproductive number of COVID-19 is higher compared to SARS coronavirus”. Journal of Travel Medicine (2020).
2. Tuite AR., et al. “Estimation of COVID-19 outbreak size in Italy”. The Lancet Infectious Diseases5 (2020): 537.
3. Torales J., et al. “The outbreak of COVID-19 coronavirus and its impact on global mental health”. International Journal of Social Psychiatry (2020).
4. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China”. JAMA11 (2020): 1061-1069.
5. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. The Lancet 10223 (2020): 507-513.
6. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet 10223 (2020): 497-506.
7. Singhal T. “A review of coronavirus disease-2019 (COVID-19)”. The Indian Journal of Pediatrics (2020): 1-6.
8. Vardavas CI and Nikitara K. “COVID-19 and smoking: A systematic review of the evidence”. Tobacco Induced Diseases 18 (2020).
9. Cortegiani A., et al. “A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19”. Journal of Critical Care (2020).
10. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell (2020).
11. Mulangu S., et al. “A randomized, controlled trial of Ebola virus disease therapeutics”. New England Journal of Medicine24 (2019): 2293-2303.
12. Mair-Jenkins J., et al. “The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis”. The Journal of infectious diseases1 (2015): 80-90.
13. Tian X., et al. “Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody”. Emerging Microbes and Infections1 (2020): 382-385.
14. Shanmugaraj, B., et al. “Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)”. Asian Pacific Journal of Allergy and Immunology 1 (2020): 10-18.
15. Michot JM., et al. “Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report”. Annals of Oncology (2020).
16. Zhang B., et al. “Immune phenotyping based on neutrophilto-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19”. medRxiv (2020).
17. Zhao J., et al. “Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”. Clinical Infectious Diseases (2020).
18. Vaishya R., et al. “Artificial Intelligence (AI) applications for COVID-19 pandemic”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2020).
19. Agnandji ST., et al. “Phase 1 trials of rVSV Ebola vaccine in Africa and Europe”. New England Journal of Medicine17 (2016): 1647-1660.
20. Zhang N., et al. “Recent advances in the detection of respiratory virus infection in humans”. Journal of Medical Virology4 (2020): 408-417.
21. Mackenzie JS and Jeggo M. “Reservoirs and vectors of emerging viruses”. Current Opinion in Virology2 (2013): 170-179.
22. Cepi to fund three programmes to develop vaccines against the novel coronavirus, ncov-2019.
23. Yong CY., et al. “Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus”. Frontiers in Microbiology 10 (2019): 1781.
24. Inovio’s Positive First-Inhhuman Mers Vaccine Results Published in the Lancet Infectious Diseases; Athena Information Solutions Pvt. Ltd.: Mumbai, India (2019).
25. Developing therapeutics and vaccines for coronaviruses (2020).
26. Liu WJ., et al. “T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV”. Antiviral Research 137 (2017): 82-92.
27. Chan KS., et al. “Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study”. Hong Kong Medical Journal (2003).
28. Yao TT., et al. “A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option”. Journal of Medical Virology6 (2020): 556-563.
29. Elfiky AA. “Anti-HCV, nucleotide inhibitors, repurposing against COVID-19”. Life Sciences (2020): 117477.
30. Holshue ML., et al. “First case of 2019 novel coronavirus in the United States”. New England Journal of Medicine (2020).
31. Dong L., et al. “Discovering drugs to treat coronavirus disease 2019 (COVID-19)”. Drug Discoveries and Therapeutics1 (2020): 58-60.
32. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. Bioscience Trends (2020).
33. Jie Z., et al. “Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia”. Zhonghua Jie He He Hu Xi Za Zhi3 (2020): 185-188.
34. Touret F and de Lamballerie X. “Of chloroquine and COVID-19”. Antiviral Research (2020): 104762.
35. Colson P., et al. “Chloroquine for the 2019 novel coronavirus SARS-CoV-2”. International Journal of Antimicrobial Agents3 (2020): 105923.
36. Roques P., et al. “Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection”. Viruses5 (2018): 268.
37. Singh AK., et al. “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews (2020).
38. Gothberg LA. “Severe infectious mononucleosis treated with chloroquine phosphate”. Journal of the American Medical Association 1 (1960): 53-57.
39. Mehra MR., et al. “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”. The Lancet (2020).
40. Jakhar D and Kaur I. “Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus”. Nature Medicine5 (2020): 632-632.
41. Wrapp D., et al. “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation”. Science 367 (6483): 1260-1263.
42. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. Nature 7798 (2020): 270-273.
43. Zeng QL., et al. “Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019”. The Journal of Infectious Diseases1 (2020): 38-43.
44. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. The Lancet 10223 (2020): 497-506.
45. Arabi YM., et al. “Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome”. American Journal of Respiratory and Critical Care Medicine6 (2018): 757-767.
46. Yang Z., et al. “The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis”. Journal of Infection (2020).
47. Zha L., et al. “Corticosteroid treatment of patients with coronavirus disease 2019 (COVID‐19)”. Medical Journal of Australia9 (2020): 416-420.
48. Russell B., et al. “COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?”. E Cancer Medical Science 14 (2020).

Citation

Citation: Soumitra Sahana., et al. “A Venture to Discover the Treatment of Coronavirus Disease 2019 (COVID 19): SARS-CoV-2". Acta Scientific Microbiology 3.10 (2020): 53-58.

Copyright

Copyright: © 2020 Soumitra Sahana., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.